- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Placebo, Cladribine Low Dose, Cladribine High Dose
- Other · Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 7,009
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Ravulizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
- Conditions
- Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
- Interventions
- Everolimus, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 8 more
- Conditions
- Kidney Disease
- Interventions
- GSK4771261, Placebo matching GSK4771261
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alcohol Use Disorder
- Interventions
- Naltrexone, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Volunteers
- Interventions
- MRT-6160, Placebo
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Migraine
- Interventions
- Timolol, Placebo
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- MLR-1023, Placebo
- Drug · Other
- Lead sponsor
- Melior Pharmaceuticals
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Dementia
- Interventions
- Methylphenidate Extended Release Oral Capsule, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
- Interventions
- ornithine phenylacetate, placebo intravenous infusion
- Drug
- Lead sponsor
- Ocera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
- Conditions
- Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions
- Entospletinib, Placebo, Cytarabine, Anthracycline
- Drug
- Lead sponsor
- Kronos Bio
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- Placebo for Treatment A, Mitapivat 100 mg, Placebo for Treatment B, Mitapivat 300 mg, Placebo for Treatment C
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-APOC3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 8
- States / cities
- North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more
- Conditions
- Myositis
- Interventions
- Nipocalimab, Placebo, Glucocorticoids
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 82
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Placebo, Sotagliflozin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 17
- States / cities
- Concord, California • Ventura, California • Denver, Colorado + 14 more
- Conditions
- Asthma
- Interventions
- Ginger Extract, Placebo
- Drug
- Lead sponsor
- Emily DiMango, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Urinary Incontinence
- Interventions
- solifenacin succinate, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Acarbose, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Metabolism, Liver Function, Pharmacokinetics
- Interventions
- Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation, Cannabidiol (CBD) Gum Arabic, sorbitol base formulation, Cannabidiol (CBD) Isolate in water formulation, CBD matching Placebo
- Dietary Supplement
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
- Interventions
- Roflumilast, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 217
- States / cities
- Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
- Conditions
- OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
- Interventions
- Serotonergic Psychedelic, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Hamden, Connecticut • West Haven, Connecticut
- Conditions
- Eosinophilic Asthma
- Interventions
- KT-621, Placebo
- Drug · Other
- Lead sponsor
- Kymera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 34
- States / cities
- Lancaster, California • Long Beach, California • Northridge, California + 28 more